Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775981 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
A Phase 1 study, sponsored by Pharmaceutical Project Solutions.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02775981: Completed Phase 1 study, sponsored by Pharmaceutical Project Solutions.
NCT02775981 is a Phase 1 study that has completed, run by Pharmaceutical Project Solutions. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02775981, a Phase 1 study, has completed, sponsored by Pharmaceutical Project Solutions.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration. The secondary objective is to evaluate the safety and tolerability of intranasal RX0041-002 in subjects with normal hepatic function and hepatic impairment.
Interventions
- DRUG RX0041-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-02 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775981
The ClinicalTrials.gov registry entry for NCT02775981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmaceutical Project Solutions, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RX0041-002 is the first listed.
NCT02775981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02775981 about?
NCT02775981 is a clinical study titled "Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function". The primary objective of this study is to evaluate the potential effect of hepatic impairment on the systemic pharmacokinetics of RX0041-002 following single dose intranasal administration. The secondary objective is to evaluate the safety and tolerability of intranasal RX0041-002 in subjects with n...
What is the current status of trial NCT02775981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-02. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02775981?
The interventions under investigation include: RX0041-002 (DRUG).
Who is sponsoring clinical trial NCT02775981?
This trial is sponsored by Pharmaceutical Project Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.